Literature DB >> 22522289

Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.

Timothy Rawson1, David Muir, Nicola E Mackie, Lucy J Garvey, Alex Everitt, Alan Winston.   

Abstract

BACKGROUND: Cerebrospinal fluid (CSF) HIV RNA load may be associated with central nervous system (CNS) disease in HIV infected subjects. We investigated parameters associated with CSF HIV RNA within a large clinical cohort.
METHODS: All HIV infected subjects undergoing CSF examination including assessment of CSF HIV RNA at St. Mary's Hospital, London, UK between January 2008 and October 2010 were included. Parameters associated with a detectable CSF HIV RNA load were assessed using linear regression modelling. CSF viral escape was defined as CSF RNA >0.5 log(10) copies/mL greater than plasma HIV RNA and >200 copies/mL where plasma HIV RNA <50 copies/mL.
RESULTS: Of 142 subjects, 99 were receiving antiretroviral therapy (ART). Plasma HIV RNA was <50 copies/mL in 69 subjects. CSF examination was performed for investigation of presumed HIV encephalopathy (IxHE, n = 57), other CNS diseases considered HIV related (n = 39), syphilis (n = 20) and CNS presentations not considered HIV related (n = 26). CSF viral escape was present in 30/142 (21%) subjects overall and in 9/69 (13%) of those on ART with undetectable plasma HIV RNA. Overall, plasma HIV RNA load was significantly associated with detectable CSF HIV RNA (p ≤ 0.001). In subjects with plasma HIV RNA <50 copies/mL, only CNS penetration effectiveness (CPE, 2008) score of <2 was significantly associated with detectable CSF HIV RNA (p = 0.044). In patients undergoing LP for IxHE both plasma HIV RNA and CPE scores were independently associated with detectable CSF HIV RNA (p = 0.019 &amp; 0.003 respectively) which was not observed in subjects undergoing CSF examination for other medical reasons.
CONCLUSIONS: In a clinical setting, CSF viral escape is observed frequently in 21% of subjects and is associated with different parameters depending on the clinical scenario.
Copyright © 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22522289     DOI: 10.1016/j.jinf.2012.04.007

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  28 in total

Review 1.  Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.

Authors:  Luisa Fiandra; Amedeo Capetti; Luca Sorrentino; Fabio Corsi
Journal:  J Neuroimmune Pharmacol       Date:  2016-11-10       Impact factor: 4.147

2.  Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV.

Authors:  Ting Ting Lee; Gursharan Chana; Paul R Gorry; Anne Ellett; Chad A Bousman; Melissa J Churchill; Lachlan R Gray; Ian P Everall
Journal:  J Neurovirol       Date:  2015-06-03       Impact factor: 2.643

3.  Raltegravir resistance in the cerebrospinal fluid.

Authors:  B Mora-Peris; N E Mackie; D Suan; D A Cooper; B J Brew; A Winston
Journal:  Infection       Date:  2013-02-03       Impact factor: 3.553

4.  Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape.

Authors:  Sérgio Monteiro de Almeida; Indianara Rotta; Ana Paula de Pereira; Bin Tang; Anya Umlauf; Cléa Elisa Lopes Ribeiro; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2020-01-30       Impact factor: 2.643

Review 5.  CNS Persistence of HIV-1 in Children: the Untapped Reservoir.

Authors:  Ann Chahroudi; Thor A Wagner; Deborah Persaud
Journal:  Curr HIV/AIDS Rep       Date:  2018-10       Impact factor: 5.071

6.  HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment.

Authors:  Arun K Ghosh; Anindya Sarkar; Hiroaki Mitsuya
Journal:  Med Res Arch       Date:  2017-04-15

Review 7.  Update on HIV dementia and HIV-associated neurocognitive disorders.

Authors:  Bruce J Brew; Phillip Chan
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

Review 8.  HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.

Authors:  Phillip Chan; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

Review 9.  Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.

Authors:  Andrea Calcagno; Giovanni Di Perri; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

10.  Incidence of symptomatic CSF viral escape in HIV infected patients receiving atazanavir/ritonavir (ATV/r)-containing ART: a tertiary care cohort in western India.

Authors:  Atul K Patel; Ketan K Patel; Swati Gohel; Ambuj Kumar; Scott Letendre
Journal:  J Neurovirol       Date:  2018-04-24       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.